Condition: Glioma · CNS Tumor, Adult · CNS Tumor, Childhood · Sponsor: Centre Leon Berard
This clinical trial is a 2-phase trial designed to evaluate the safety of tarlatamab in combination with a fixed dose of metronomic temozolomide in adolescents and adults with CNS tumors (stratified into two age-based cohorts), and to assess the clinical activity of this therapeutic strategy in three parallel, histology-defined cohorts (IDH-mutant glioma, other gliomas, and other CNS tumors). A pre-screening to detect DLL3 expression by IHC on archival tumor sample must be performed before the therapeutic part. Only patients with DLL3 positive tumor on IHC can be enrolled in the therapeutic part. This pre-screening must be optimally performed during the ongoing treatment line i.e. before documented progression to not delay treatment starts at time of progression. Tumor samples (surgery or biopsy specimen) will be sent to a central lab for IHC testing.
This description comes directly from the study's public registry record.
Pierre LEBLOND, MD, PhD · +33469166550 · pierre.leblond@ihope.fr
Aurélien MAUREILLE, MD · +33469166645 · aurelien.maureille@lyon.unicancer.fr
Always discuss trial participation with your own doctor first.
| Institut de Cancérologie de l'Ouest | Angers, France | Recruiting |
| Hôpital Universitaire d'Angers | Angers, France | Not Yet Recruiting |
| CHU de Bordeaux | Bordeaux, France | Not Yet Recruiting |
| Hôpital Saint-André | Bordeaux, France | Not Yet Recruiting |
| Hôpital Neurologique Pierre Wertheimer | Bron, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Not Yet Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| Hôpital de la Timone - service adulte | Marseille, France | Recruiting |
| Hôpital de la Timone - service pédiatrie | Marseille, France | Recruiting |
| Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix | Paris, France | Not Yet Recruiting |
| IUCT - Claudius Regaud | Toulouse, France | Recruiting |
| Institut Gustave Roussy | Villejuif, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07243470